Drug Approval | January 02, 2025
Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Merck has also decided to end the favezelimab clinical development program
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company will also share results in two additional posters for deuruxolitinib
Subscribe To Our Newsletter & Stay Updated
